AlmataBio Acquired by Avalo Therapeutics | Healthcare M&A Deal

Avalo Therapeutics has completed the acquisition of AlmataBio, a pharmaceuticals business in Pennsylvania, for $2.25 million under an optional milestone buyout. Avalo Therapeutics acquisitions focus on IL-1β based immune-mediated inflammatory disease treatments, while AlmataBio contributed pharmaceutical development capabilities tied to Phase 3 milestone economics in healthcare M&A. The public company acquisition supports Avalo’s clinical-stage pipeline, including abdakibart (AVTX-009) in hidradenitis suppurativa, with Wayne, Pa. as the buyer’s base. The other acquisition is structured as a milestone buyout option with an exercisable 90-day window, adding $5.125 million in cash or Avalo stock in lieu of a previously disclosed $15 million contingent payment, as part of healthcare deals PA and PA acquisitions.